… Inc. COR on Wednesday reported third-quarter 2025 sales increased 8.7% … quarter, driven by our pharmaceutical-centric strategy and focus on … $3.82. Adjusted gross profit reached $2.9 billion, … Solutions segment. Cencora expects adjusted earnings to be $15.85-$ …

… growth in medical products and pharmaceuticals, particularly — sorry, … and endodontic consumables. Profits were also bolstered by … initiatives on our upcoming third quarter earnings call. Regarding share repurchases … first is driving gross profit. Now I don’t …

… for the third quarter of fiscal year 2025. Our third quarter earnings press … discontinued operations. In the third quarter, we recorded an additional … continued softness among key pharma accounts. The decline was … cleaning up, which explains 3Q to Q4. I’m …

… trading after reporting fiscal third quarter earnings that exceeded expectations. On … full-year revenue guidance. Pharmaceutical and agricultural giant Bayer … growth in sales and profits during the second quarter … after posting a quarterly profit drop. U.S. …

… 19 products and other pharmaceutical sales. The company … licensing deal with Chinese drugmaker 3SBio. According to Denton … third quarter. Without the charge, Pfizer would have raised its adjusted profit … Pfizer’s second-quarter earnings reflect a critical point …

… Lending Corporation misses on earnings expectations. Reported EPS … Thank you, operator. Our third quarter earnings release, which we issued … Alto, a digital pharmacy company which was merged … a comprehensive platform combining pharmacy, diagnostics and virtual …

… buyback program and forecasting third-quarter bookings above Wall … in the third quarter," and "earnings growth to … small tariff" on pharmaceutical imports before hiking it … cloud networking firm forecast third-quarter revenue above analysts…

… buyback program and forecasting third-quarter bookings above Wall … in the third quarter," and "earnings growth to … small tariff" on pharmaceutical imports before hiking it … cloud networking firm forecast third-quarter revenue above analysts…

Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment …

… 126 million in the third quarter of 2025 and … profits through small and mid-cap biotechnology companies to leading global pharmaceutical … companies. Royalty Pharma has … expense     Equity in earnings of equity method investees …